AR112069A1 - Inmunoglobulinas que fijan aggrecan - Google Patents
Inmunoglobulinas que fijan aggrecanInfo
- Publication number
- AR112069A1 AR112069A1 ARP180101495A ARP180101495A AR112069A1 AR 112069 A1 AR112069 A1 AR 112069A1 AR P180101495 A ARP180101495 A AR P180101495A AR P180101495 A ARP180101495 A AR P180101495A AR 112069 A1 AR112069 A1 AR 112069A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunoglobulins
- polypeptides
- aggrecan
- bind
- bind aggrecan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Inmunoglobulinas que fijan específicamente a Aggrecan y más particularmente a polipéptidos, ácidos nucleicos que codifican a tales polipéptidos; a métodos para preparar tales polipéptidos; a composiciones y en particular a composiciones farmacéuticas que contienen tales polipéptidos, para propósitos profilácticos, terapéuticos o de diagnóstico. En particular, las inmunoglobulinas inhiben la actividad de Aggrecan.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762514180P | 2017-06-02 | 2017-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112069A1 true AR112069A1 (es) | 2019-09-18 |
Family
ID=62620830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101495A AR112069A1 (es) | 2017-06-02 | 2018-06-04 | Inmunoglobulinas que fijan aggrecan |
Country Status (14)
Country | Link |
---|---|
US (2) | US11603401B2 (es) |
EP (1) | EP3630818A1 (es) |
JP (2) | JP7320457B2 (es) |
KR (1) | KR20200013247A (es) |
CN (2) | CN118085076A (es) |
AR (1) | AR112069A1 (es) |
BR (1) | BR112019025392A2 (es) |
CA (1) | CA3065630A1 (es) |
IL (1) | IL270969A (es) |
MX (1) | MX2019014504A (es) |
NZ (1) | NZ759601A (es) |
SG (1) | SG10202113337YA (es) |
TW (1) | TWI811220B (es) |
WO (1) | WO2018220225A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108659121A (zh) | 2011-06-23 | 2018-10-16 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
CN110177875B (zh) | 2016-11-28 | 2023-11-28 | 中外制药株式会社 | 包含抗原结合结构域和运送部分的多肽 |
JP7438180B2 (ja) * | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗lag-3抗体ポリペプチド |
JP7414736B2 (ja) * | 2018-05-30 | 2024-01-16 | 中外製薬株式会社 | アグリカン結合ドメインおよび運搬部分を含むポリペプチド |
WO2023086441A1 (en) * | 2021-11-12 | 2023-05-19 | Regents Of The University Of Minnesota | Compositions and methods for transcriptional activation |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
DK0702721T3 (da) | 1993-06-09 | 2001-05-21 | Unilever Nv | Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
WO1998022141A2 (en) | 1996-11-19 | 1998-05-28 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
CA2321199A1 (en) | 1998-02-19 | 1999-08-26 | William A. Brady | Compositions and methods for regulating lymphocyte activation |
EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
AU3041100A (en) | 1999-01-05 | 2000-07-24 | Unilever Plc | Binding of antibody fragments to solid supports |
AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
EP1157119A1 (en) | 1999-02-05 | 2001-11-28 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
CA2367955C (en) | 1999-03-15 | 2009-05-19 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
AU776824B2 (en) | 1999-04-22 | 2004-09-23 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
CA2375781A1 (en) | 1999-06-18 | 2000-12-28 | Cv Therapeutics, Inc. | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abci |
WO2001009300A2 (en) | 1999-08-02 | 2001-02-08 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
DK1242460T3 (da) | 1999-11-29 | 2006-12-11 | Unilever Nv | Immobilisering af proteiner ved hjælp af et polypeptidsegment |
ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
AU784285B2 (en) | 1999-12-24 | 2006-03-02 | Genentech Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
EP1134231B1 (en) | 2000-03-14 | 2009-04-15 | Unilever N.V. | Antibody heavy chain variable domains against human dietary lipases, and their uses |
AU2001268855A1 (en) | 2000-05-26 | 2001-12-03 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
ATE513854T1 (de) | 2000-12-13 | 2011-07-15 | Bac Ip B V | Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
EP1456237A2 (en) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Method for cloning of variable domain sequences |
WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
US7521543B2 (en) | 2002-10-23 | 2009-04-21 | Ludwig Institute For Cancer Research | A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
AU2003286003B2 (en) | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
DE60329627D1 (de) | 2002-12-31 | 2009-11-19 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン.ヴェー. | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
CN101443043A (zh) * | 2003-10-08 | 2009-05-27 | 杜门蒂斯有限公司 | 抗体组合物和方法 |
ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
WO2006079372A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
CA2960105A1 (en) * | 2005-05-20 | 2006-11-23 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
WO2007045661A1 (en) * | 2005-10-20 | 2007-04-26 | Nordic Bioscience Diagnostics A/S | Detection or quantification of aggrecan and its fragments |
GB0521392D0 (en) * | 2005-10-20 | 2005-11-30 | Nordic Bioscience As | Detection or quantification of aggrecan and its fragments |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
CN101611056A (zh) | 2006-12-05 | 2009-12-23 | 埃博灵克斯股份有限公司 | 能够结合于血清蛋白的肽 |
CA2678218A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
PT2842573T (pt) | 2008-11-07 | 2017-12-04 | Galaxy Biotech Llc | Anticorpos monoclonais para o recetor 2 do factor de crescimento de fibroblastos |
JP5647222B2 (ja) | 2009-04-10 | 2014-12-24 | アブリンクス エン.ヴェー. | Il−6r関連疾患及び障害の治療のためのil−6rに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド |
CN108659121A (zh) | 2011-06-23 | 2018-10-16 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
AU2014335251B2 (en) * | 2013-10-15 | 2020-04-30 | Genefrontier Corporation | Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases |
-
2018
- 2018-06-04 CA CA3065630A patent/CA3065630A1/en active Pending
- 2018-06-04 AR ARP180101495A patent/AR112069A1/es unknown
- 2018-06-04 SG SG10202113337YA patent/SG10202113337YA/en unknown
- 2018-06-04 TW TW107119235A patent/TWI811220B/zh active
- 2018-06-04 CN CN202410199258.2A patent/CN118085076A/zh active Pending
- 2018-06-04 BR BR112019025392-0A patent/BR112019025392A2/pt unknown
- 2018-06-04 NZ NZ759601A patent/NZ759601A/en unknown
- 2018-06-04 EP EP18731372.1A patent/EP3630818A1/en active Pending
- 2018-06-04 KR KR1020197038735A patent/KR20200013247A/ko not_active Application Discontinuation
- 2018-06-04 WO PCT/EP2018/064608 patent/WO2018220225A1/en active Application Filing
- 2018-06-04 CN CN201880048748.5A patent/CN110997716B/zh active Active
- 2018-06-04 JP JP2019566695A patent/JP7320457B2/ja active Active
- 2018-06-04 US US16/617,025 patent/US11603401B2/en active Active
- 2018-06-04 MX MX2019014504A patent/MX2019014504A/es unknown
-
2019
- 2019-11-27 IL IL270969A patent/IL270969A/en unknown
-
2022
- 2022-12-23 US US18/145,989 patent/US20230312694A1/en active Pending
-
2023
- 2023-07-24 JP JP2023119575A patent/JP2023153140A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3065630A1 (en) | 2018-12-06 |
AU2018277310A1 (en) | 2019-12-12 |
JP7320457B2 (ja) | 2023-08-03 |
NZ759601A (en) | 2023-06-30 |
JP2020522515A (ja) | 2020-07-30 |
WO2018220225A1 (en) | 2018-12-06 |
BR112019025392A2 (pt) | 2020-07-07 |
US11603401B2 (en) | 2023-03-14 |
US20220089703A9 (en) | 2022-03-24 |
TW201902930A (zh) | 2019-01-16 |
US20230312694A1 (en) | 2023-10-05 |
IL270969A (en) | 2020-01-30 |
EP3630818A1 (en) | 2020-04-08 |
RU2019143589A3 (es) | 2021-08-16 |
SG10202113337YA (en) | 2021-12-30 |
JP2023153140A (ja) | 2023-10-17 |
RU2019143589A (ru) | 2021-07-09 |
CN110997716A (zh) | 2020-04-10 |
US20200140532A1 (en) | 2020-05-07 |
TWI811220B (zh) | 2023-08-11 |
CN118085076A (zh) | 2024-05-28 |
US20210115117A9 (en) | 2021-04-22 |
CN110997716B (zh) | 2024-03-15 |
KR20200013247A (ko) | 2020-02-06 |
MX2019014504A (es) | 2020-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112069A1 (es) | Inmunoglobulinas que fijan aggrecan | |
CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
UY37463A (es) | Proteínas de unión | |
BR112018012707A2 (pt) | inibidores da interação de menin-mll | |
BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
EA201492221A1 (ru) | Полипептиды, имеющие активность трансгалактозилирования | |
BR112016029906A2 (pt) | compostos excipientes redutores de viscosidade para formulações proteicas | |
UY36561A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
CO6950477A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
BR112018012262A2 (pt) | composições de interleucina-15 e seus usos | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
ECSP18046820A (es) | Polipéptidos que inhiben cd40l | |
BR112016027024A2 (pt) | polipeptídeos de ligação específica e seus usos | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
BR112017022523A2 (pt) | ?formulação para cápsulas de gel, cápsula de gel, e, processo?. | |
EA201791716A1 (ru) | Фармацевтический состав | |
MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
BR112017016388A2 (pt) | cenicriviroc para o tratamento da fibrose | |
BR112016012002A2 (pt) | Vitanolídeos úteis para o tratamento de doenças neurodegenerativas | |
EA201990181A1 (ru) | Получение активированных клостридиальных нейротоксинов | |
EA201892157A1 (ru) | Фосфаплатиновые жидкие составы |